Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.47 |
| ▸ | CTSL | P07711 | 4/20 | 0.47 |
| ▸ | CTSB | P07858 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13141751 | 0.86 | CTSS (0.39) | CTSSCTSLCTSBALDH1A1GAA | |
| SCHEMBL26700837 | 0.78 | ALDH1A1 (0.46) | ALDH1A1GAATSHREPHX1MEN1 | |
| SCHEMBL9951748 | 0.77 | FKBP1A (0.47) | CTSSCTSLCTSBALDH1A1GAA | |
| SCHEMBL18069841 | 0.76 | CTSB (0.47) | CTSSCTSLCTSBALDH1A1GAA | |
| SCHEMBL19040173 | 0.76 | CTSB (0.47) | CTSSCTSLCTSBALDH1A1GAA | |
| SCHEMBL24571689 | 0.76 | ALDH1A1 (0.44) | CTSSCTSLCTSBALDH1A1GAA | |
| SCHEMBL13733943 | 0.76 | EPHX2 (0.50) | CTSSCTSLCTSBALDH1A1GAA | |
| SCHEMBL28141039 | 0.76 | ALDH1A1 (0.49) | CTSSCTSLCTSBALDH1A1GAA | |
| SCHEMBL7440304 | 0.75 | CTSB (0.49) | CTSSCTSLCTSBALDH1A1GAA | |
| SCHEMBL7440294 | 0.75 | CTSB (0.49) | CTSSCTSLCTSBALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135215-A1 | COMPOUNDS AS CDK2/4/6 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| EP-4110782-A1 | COMPOUNDS AS CDK2/4/6 INHIBITORS | Fochon Biosciences, Ltd. (CN) | 2023-01-04 | — | — | EP | disclosed |
| CN-115551856-A | Compounds as CDK2/4/6 inhibitors | 重庆复尚源创医药技术有限公司 | 2022-12-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135215-A1 | COMPOUNDS AS CDK2/4/6 INHIBITORS | CDK2, CDK6, CDK20 | CTSS 3211/4885CTSL 1629/4885CTSB 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.